425: Indivior Pharmaceuticals Reports Strong Q2 2026 Results, Raises Guidance

Indivior Pharmaceuticals announced robust second quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year guidance, alongside progress on its merger with Supernus.

Summary

• Indivior Pharmaceuticals reported strong financial results for the second quarter of 2026, with total net revenue of $343 million, a 14% increase year-over-year.
• SUBLOCADE net revenue reached a record $253 million in Q2 2026, up 21% year-over-year, driven by a 18% increase in dispense unit volume in the U.S.
• The company achieved record quarterly GAAP net income of $122 million and non-GAAP net income of $142 million.
• Adjusted EBITDA also hit a record at $186 million, an increase of 111% year-over-year.
• Indivior raised its full-year 2026 financial guidance, now expecting total net revenue between $1,295 million and $1,365 million, and Adjusted EBITDA between $700 million and $740 million.
• The company repurchased approximately 4.7 million shares in Q2 2026 for $175 million.
• A definitive agreement to merge with Supernus Pharmaceuticals is progressing, with completion expected in the fourth quarter of 2026.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong financial performance, raised guidance, and strategic progress, including the proposed merger.

Positives

• Total net revenue increased by 14% year-over-year to $343 million in Q2 2026.
• SUBLOCADE net revenue saw a significant 21% year-over-year increase to $253 million, with U.S. revenue up 22% driven by 18% dispense unit volume growth.
• Record quarterly GAAP net income of $122 million ($0.98 diluted EPS) and non-GAAP net income of $142 million ($1.15 diluted EPS) were achieved.
• Adjusted EBITDA surged by 111% year-over-year to $186 million, with the Adjusted EBITDA margin improving by 25 percentage points to 54%.
• Full-year 2026 guidance was raised, with total net revenue now projected between $1,295 million and $1,365 million (a 7% increase at the midpoint) and Adjusted EBITDA between $700 million and $740 million (a 68% increase at the midpoint).
• The company returned $175 million to shareholders through share repurchases in Q2 2026, totaling $300 million year-to-date.
• Two new real-world evidence studies demonstrated positive outcomes for SUBLOCADE in managing opioid use disorder (OUD).

Negatives

• While not explicitly negative, the company's balance sheet shows a stockholders deficit of $208 million as of June 30, 2026, an increase from $98 million at the end of 2025, primarily due to accumulated deficit.
• The company has significant accrued rebates and product returns ($610 million) and long-term debt ($487 million plus current portion).

Risks

• The proposed merger with Supernus may not be completed on the anticipated timeline or at all, due to potential failure to obtain required stockholder or regulatory approvals, or the imposition of unfavorable conditions.
• Restrictions during the pendency of the transaction may limit Indivior's ability to pursue business opportunities or strategic transactions.
• The anticipated benefits, synergies, growth, profitability, cash flow generation, and earnings accretion of the merger may not be realized or may be realized more slowly than expected.
• Integration of the two businesses may involve difficulties, costs, and risks.
• Future sales of products could be lower than expected.
• Greater than expected impacts from competition could affect financial performance.
• Unanticipated costs, including the effects of potential tariffs and retaliatory tariffs, could arise.
• Market conditions and decisions of third parties outside of Indivior's control could impact business development opportunities.

Future Outlook

Full-year 2026 guidance has been raised, with expectations for total net revenue between $1,295 million and $1,365 million and Adjusted EBITDA between $700 million and $740 million. The company anticipates continued acceleration in SUBLOCADE net revenue and dispense unit growth, and expects to close its merger with Supernus in Q4 2026.

Management Comments

• "Exceptional operational execution in Phase II Accelerate of the Indivior Action Agenda fueled strong SUBLOCADE performance in the quarter and is the primary driver of our raised 2026 guidance," said Joe Ciaffoni, Chief Executive Officer.
• "We remain focused on Phase II Accelerate for the remainder of 2026 and look forward to closing our proposed merger with Supernus, which is expected in the fourth quarter."
• "We delivered record SUBLOCADE net revenue and adjusted EBITDA in the quarter leading us to raise our 2026 guidance," said Ryan Preblick, Chief Financial Officer.
• "We are committed to creating long-term shareholder value."

Industry Context

StockSavvy.ai notes that Indivior's strong performance, particularly with SUBLOCADE, aligns with the growing market for long-acting injectables in treating opioid use disorder. The proposed merger with Supernus aims to create a larger, diversified CNS-focused biopharmaceutical company, a common strategy for achieving scale and expanding market reach in the competitive pharmaceutical landscape.

Comparison to Industry Standards

• Indivior's SUBLOCADE net revenue growth of 21% YoY in Q2 2026 significantly outpaces the average growth rates seen in many established pharmaceutical product categories, indicating strong market penetration and demand.
• The 111% year-over-year increase in Adjusted EBITDA and the resulting margin expansion (to 54%) suggest superior operational efficiency and cost management compared to industry peers, especially within the specialty pharmaceutical sector.
• The raised full-year guidance, particularly for Adjusted EBITDA (projected 68% YoY growth), indicates a performance trajectory that is likely exceeding industry benchmarks for companies of similar size and stage in the CNS therapeutic area.

Stakeholder Impact

• Shareholders are likely to benefit from the strong financial performance, raised guidance, and the potential value creation from the merger with Supernus, as well as ongoing share repurchases.
• Patients with opioid use disorder will continue to have access to SUBLOCADE, with evidence suggesting improved outcomes and reduced relapse risk.
• Employees may experience changes related to the proposed merger with Supernus, which aims to create a leading CNS-focused biopharmaceutical company.

Next Steps

• Continue to focus on Phase II Accelerate of the Indivior Action Agenda.
• Work towards closing the proposed merger with Supernus Pharmaceuticals, expected in Q4 2026.
• Execute Phase III Breakout initiatives following the merger close.
• Continue to drive SUBLOCADE dispense unit and net revenue growth.

Key Dates

Recommendation

The company delivered exceptionally strong Q2 results, significantly exceeding prior expectations and demonstrating robust growth in its key product, SUBLOCADE. The raised full-year guidance, coupled with the strategic advancement of the Supernus merger, positions Indivior for substantial future value creation. The combination of operational excellence, strategic M&A, and shareholder capital return warrants a strong buy recommendation.

Keywords

SUBLOCADE, Opioid Use Disorder, OUD, Financial Results, Guidance, Merger, Supernus Pharmaceuticals, Adjusted EBITDA